TY  - JOUR
TI  - New Trials Comparing Protease Inhibitors and Nonnucleoside Analogs will Assess Reductions in Cardiovascular Risk Besides Antiviral Efficacy in First-line Therapies
AU  - No especificado
DO  - No especificado
ER  -